chronic non-specific low back pain
Conditions
Interventions
drugs group:Loxoprofen sodium (3times 60 mg per day) for four weeks.Eperisone (3 times 50mg per day) for wour weeks
the rESWT group:1.One rESWT session per week
2.4 × 1000 rESWs per session (1000rESWs each applied to the left and the right paravertebrate muscles above L3 to S1 using the 36-mm applicator, plus 1000rESWs each applied to the left and the right s
the rESWT plus L-E drugs group:In combination, the specific treatment method is the same as above
Sponsors
First Affiliated Hospital of Zhejiang University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Willingness of the patient to participate in the study, and written informed consent signed and personally dated by the patient; 2. Aged between 18 and 80 years; 3. Both male and female with non-specific low back pain for more than three month; 4. Subjects were able to follow the drug dose and visit plan; 5. Can describe the symptoms objectively, can cooperate actively, without any mental disorders; 6. No contraindications for rESWT.
Exclusion criteria
Exclusion criteria: 1. The general situation is poor, cannot objectively describe the symptom, or has the serious infection, the respiratory function is not complete, cannot cooperate actively; 2. Contraindications of L-E drug treatment; 3. Previous spinal fracture or spinal surgery; 4. Protrusion of a lumbar intervertebral disk, ankylosing spondylitis, scoliosis, lumbar spondylolisthesis and lumbar spondylolysisotreatment of patients with local tumors; 5. treatment of patients with local bacterial and/or viral infections (including lumbar vertebral tuberculosis); 6. treatment of patients with blood-clotting disorders (including local thrombosis)otreatment of patients treated with oral anticoagulations; 7. treatment of patients treated with local corticosteroid applications in the time period of six weeks before the first rESWT session (if applicable); 8. Patients with severe peptic ulcer, pancreatitis, intestinal obstruction, asthma, cardiovascular disease, etc; 9. suspect or do have a history of drug abuse; 10. treatment of pregnant or lactating women; 11. Participation in any other clinical trial in the time period of 12 weeks before potential inclusion in the proposed study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSEQ; | — |
Secondary
| Measure | Time frame |
|---|---|
| NRS;PHQ-9;OLDPDQ; | — |
Countries
China
Contacts
Public ContactZhiying Feng
First Affiliated Hospital of Zhejiang University
Outcome results
None listed